Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Anticorps > Anticorps pour Cytométrie en Flux

Anti-Human PD-L1 Recombinant Antibody (22C3) (HV974207)

Anti-Human PD-L1 Recombinant Antibody (22C3)
Anti-Human PD-L1 Recombinant Antibody (22C3)
Anti-Human PD-L1 Recombinant Antibody (22C3)
Anti-Human PD-L1 Recombinant Antibody (22C3)
Anti-Human PD-L1 Recombinant Antibody (22C3)
Anti-Human PD-L1 Recombinant Antibody (22C3)
Prix(USD) :
Spécification :
  • 50ug
  • 100ug
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHV974207
Reactivité des espècesHuman
ApplicationsFCM
Espèce hôteMouse
ClonalitéMonoclonal
IsotypeIgG1
ID de clone22C3
Applications testées FCM
Cible B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1
Niveau d'endotoxines < 10 EU/mg
Pureté >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Numéro d'accès Q9NZQ7
Forme Liquid
Tampon de stockage 0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Contexte

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410
3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417
4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419
5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298
6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077
7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Note For research use only.
Images
  • Anti-Human PD-L1 Recombinant Antibody (22C3)

    SEC-HPLC

    SEC-HPLC detection for Anti-Human CD274/PD-L1/B7-H1 Antibody (22C3).

  • Anti-Human PD-L1 Recombinant Antibody (22C3)

    Bioactivity

    Detects CD274/PD-L1/B7-H1 in indirect ELISAs.

  • Anti-Human PD-L1 Recombinant Antibody (22C3)

    Flow CytoMetry

    Flow-cytometry using anti-human CD274 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD274 monoclonal antibody (Catalog: HV974207) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Mouse IgG H&L Polyclonal Antibody, FITC (abinScience: MF690414) and cells analysed on a NovoCyte Flow Cytometer.

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs